IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment of cancer, announces today it has signed a contract with YAS Healthcare, a subsidiary of DAS Holding, to install a Proteus ONE compact proton therapy solution to be located in Dubai, United Arab Emirates (UAE).

With the acquisition of this Proteus ONE system, YAS Healthcare will establish the Gulf Cooperation Council (GCC) region’s first operational proton therapy centre, marking a major milestone in advancing cancer treatment in the UAE and beyond. YAS Healthcare expects to start treating its first patients in 2029.

The contract includes the supply of the latest generation of proton therapy system, as well as a multi-year operation and maintenance agreement. Proteus ONE is the market-leading compact proton therapy solution, upgradable over time to continue offering the latest technology to IBA users.

Olivier Legrain, Chief Executive Officer of IBA, commented: “We are honoured to have signed a contract with YAS Healthcare and to contribute to making proton therapy technology available for the benefit to the patients in this region. This new contract demonstrates the technological advancement of the IBA offering on the market, further strengthening our leadership.”

Dr. Mohammed Zaki, Medical Director & General Manager of YAS Healthcare, added: “After a rigorous selection process, we decided to partner with IBA, the global leader in the design, manufacture, and installation of cutting-edge proton therapy technology. This achievement comes just five months after YAS Healthcare secured preliminary approval from the Dubai Health Authority (DHA) to build the nation’s first proton therapy centre. We are proud to achieve this major milestone in advancing cancer treatment in the UAE.”